Juluca (Dolutegravir Sodium, Rilpivirine Hydrochloride)

• Juluca is an antiretroviral medication that targets HIV‑1 replication in adults who have previously received therapy.
• HIV‑1 infection in treatment‑experienced adults: provides virologic suppression when combined with a suitable background regimen.

• Dolutegravir sodium binds to the HIV‑1 integrase enzyme, preventing the insertion of viral DNA into the host genome, while rilpivirine hydrochloride attaches to the reverse transcriptase enzyme at a non‑nucleoside site, blocking the conversion of viral RNA to DNA. Together they halt viral replication and reduce plasma HIV RNA levels.

Juluca may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects

• Nausea: mild stomach upset reported by some patients.
• Headache: transient headache episodes.
• Fatigue: feeling of tiredness or reduced energy.
• Diarrhea: loose stools, usually self‑limiting.
• Insomnia: difficulty falling or staying asleep.
• Rash: mild skin irritation or erythema.

Serious or Rare Side Effects

• Hepatotoxicity: signs of liver injury such as jaundice.
• Severe hypersensitivity: swelling, breathing difficulty, or anaphylaxis.
• QT prolongation: cardiac rhythm changes detectable on ECG.
• Depression or mood changes: new or worsening psychiatric symptoms.
• Elevated serum creatinine: indicating possible renal impact.
• Pancreatitis: abdominal pain with elevated enzymes.

• Before initiating Juluca, consider the following safety measures.
• Baseline liver function: assess hepatic enzymes to detect pre‑existing liver disease.
• Drug resistance testing: ensure no prior resistance to integrase inhibitors or NNRTIs.
• Concomitant medications: review for potential interactions that affect drug levels.
• Pregnancy and breastfeeding: discuss risks with a healthcare professional.
• Adherence counseling: emphasize the importance of consistent daily dosing.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Juluca can interact with several drug classes; monitoring is essential.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce rilpivirine absorption.
• Rifampin or other strong enzyme inducers: markedly lower dolutegravir levels.
• Proton pump inhibitors: may decrease rilpivirine exposure.

Moderate Interactions (Monitor Closely)

• Certain anticonvulsants (e.g., carbamazepine): modestly reduce dolutegravir concentrations.
• St. John’s wort: may lower rilpivirine levels.
• Hormonal contraceptives: potential reduction in efficacy, consider alternative methods.